1315469-70-5

Basic information

• Product Name: 4-(2,5-dichlorophenoxy)pyrimidine-5-carboxylate
• Synonyms: 4-(2,5-dichlorophenoxy)pyrimidine-5-carboxylate
• CAS NO: 1315469-70-5
• Molecular Weight: 285.086
• Mol File: 1315469-70-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(2,5-dichlorophenoxy)pyrimidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2,5-dichlorophenoxy)pyrimidine-5-carboxylate(1315469-70-5)
• EPA Substance Registry System: 4-(2,5-dichlorophenoxy)pyrimidine-5-carboxylate(1315469-70-5)

Safety Data

• Hazardous Substances Data: 1315469-70-5(Hazardous Substances Data)

Upstream product

• 583-78-8 2,5-dichlorophenol 
• 1315469-71-6 ethyl 4-(2,5-dichlorophenoxy)pyrimidine-5-carboxylate 
• 4786-52-1 ethyl 4-hydroxypyrimidine-5-carboxylate 
• 41103-17-7 ethyl 4-chloropyrimidine-5-carboxylate 

Downstream Products

• 1415407-19-0 C₂₁H₁₈Cl₂N₄O₂ 
• 1415407-20-3 C₂₂H₂₀Cl₂N₄O₂ 
• 1415407-21-4 C₂₂H₂₀Cl₂N₄O₂ 
• 1415407-29-2 C₁₉H₁₃Cl₂N₃O₂S 
• 1415407-27-0 C₂₃H₂₀Cl₂N₄O₂ 
• 1415407-25-8 C₂₃H₂₂Cl₂N₄O₂ 
• 1415407-23-6 C₂₂H₁₈Cl₂N₄O₂ 
• 1415407-22-5 C₂₂H₁₈Cl₂N₄O₂ 
• 1315469-38-5 [4-(2,5-dichloro-phenoxy)-pyrimidin-5-yl]-(6-fluoro-3,4-dihydro-2H-quinolin-1-yl)-methanone 
• 1315469-41-0 4-(2,5-dichloro-phenoxy)-pyrimidine-5-carboxylic acid (2-methoxy-pyridin-3-yl)-methyl-amide 
• 1315469-37-4 [4-(2,5-dichloro-phenoxy)-pyrimidin-5-yl]-(3,4-dihydro-2H-quinolin-1-yl)-methanone 

Relevant articles and documents

Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists

4-Phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists are reported. Several 4-phenoxynicotinamide derivatives were found to activate human and mouse TGR5 (hTGR5 and mTGR5) with EC50 values in the low nanomolar range. Compound 23g, with an EC50 value of 0.72 nM on hTGR5 and an EC 50 value of 6.2 nM on mTGR5, was selected for further in vivo efficacy studies. This compound exhibited a significant dose-dependent glucagon-like peptide-1 (GLP-1) secretion effect. A single oral dose of 23g (50 mg/kg) significantly reduced blood glucose levels in db/db mice and caused a 49% reduction in the area under the blood glucose curve (AUC)0-120min following an oral glucose tolerance test (OGTT) in imprinting control region (ICR) mice. However, 23g stimulated gallbladder filling, which might result in side effects to the gallbladder.

4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS

This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula (I), wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.